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Introduction
hypertension (ht) is an important challenge to public health. 
According to statistics, in 2000 over one quarter of the adult 
population worldwide suffered from ht. it has been predicted 
that by 2025 this proportion will reach nearly 30% (29). ht 
is one of the major risk factors for ischemic heart disease, 
cerebrovascular diseases, diseases of peripheral arteries 
and other cardiovascular disease (cVD) complications. the 
effectiveness of antihypertensive therapies is well established 
and documented in terms of risk reduction for stroke and 
other cVD events (17, 18, 42). the european Society of 
hypertension and the european Society of cardiology stated 
in their guidelines that all antihypertensive therapies can be 
considered as first-line choice drugs (34). Accordingly, the costs 
of antihypertensive pharmacotherapy and cVD complications 
have become extremely important (6). cVDs can pose a great 
burden on any healthcare system. in 2003 the cost of cVD in 
the european Union was almost 105 billion euros, or 12% of 
the total healthcare expenditure (31).
Economic evaluation in health care is defined as the 
comparative analysis of alternative options in terms of their 
costs and consequences (14). Different cost models have 
been created for evaluation of the cost and cost-effectiveness 
of hypertension pharmacotherapy. lloyd et al. (32) created 
a burden-of-disease model and estimated that in the UK, in 
general, 16 million adults have blood pressure in the range 
of 140/90−160/95 mm Hg and above and that 58,000 major 
cardiovascular events per year occur in these patients. hansson 
et al. (22) estimated the burden of failing to achieve targets for 
blood pressure control in France, Germany, italy, Sweden and 
the UK by constructing a cost-of-illness model and calculated 
that 1.26 billion euros could be saved if ht management 
achieved blood pressure targets. Flack et al. (15) developed a 
model to estimate the number of cases and costs of myocardial 
infarction, stroke and congestive heart failure and, in doing 
so, discovered that inadequate control resulted in 39,702 
cardiovascular events and 8,374 deaths thus leading to $964 
million of direct medical expenditure. 
the Markov decision model, a powerful analytical tool in 
economic evaluations, allows modelling of patients’ preferences 
and costs over patients’ lifetime. Markov models have been 
constructed for the evaluation of the cost-effectiveness of 
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ABSTRACT
To date there is no Markov model to evaluate the cost-effectiveness of antihypertensive pharmacotherapies at national level in 
developing countries. The aim of our study was to evaluate different antihypertensives and determine their cost-effectiveness as 
monotherapy treatment in primary care in Serbia. 
We developed a Markov model to estimate quality-adjusted life years (QALY), lifetime costs and incremental cost-effectiveness 
of different antihypertensive medicines used in the clinical practice in Serbia (diuretic, beta blocker, Ca channel blocker and 
ACE inhibitors) to strategy “no intervention”. Cohort of 55-year-old patients with hypertension (systolic and diastolic blood 
pressure ≥140 and 90 mmHg), without cardiovascular complications was run through the model. Acute myocardial infarction, 
angina pectoris, heart failure, stroke, and total mortality were observed as outcomes. The time horizon was over a lifetime, and 
the perspective was that of a third-party payer. Annual discount rate of 5% was applied to all future costs and effects. 
The results showed small differences in QALY in strategies ACE inhibitor, beta blockers, and diuretic. The incremental cost-
effectiveness ratio (ICER) for diuretic, compared to no intervention, was €74.27/QALY. The ICER for beta blocker compared to 
diuretic was €75.58/QALY. ACE inhibitor was extended dominated by diuretic and beta blocker, while Ca channel blocker had 
higher costs and less effectiveness compared to all previous strategies. The results of the probabilistic sensitivity analysis showed 
that application of antihypertensive therapy is cost-effective even at small values of willingness to pay. 
It could be concluded that for individuals aged 55 the diuretics are the most cost-effective strategy to start monotherapy of 
hypertension.
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different antihypertensive medicines and therapies, an example 
being angiotensin-converting enzyme (Ace) inhibitors (5).
to date there is no Markov model to evaluate the cost-
effectiveness of antihypertensive pharmacotherapies at a 
national level in developing countries. the purpose of this 
study was to create a Markov model and to determine the cost-
effectiveness of different antihypertensive pharmacotherapies 
in a primary care setting in Serbia. the point of view of the 
analysis is that of a third-party payer over a life-time horizon. 
The study is important from the perspective of financing 
institutions in order to make the consequences of the current 
pharmacotherapeutic approaches in countries with scarce 
resources and limited therapy choice as clear as possible.
Materials and Methods
Model and strategies
the hypothetical cohort of 1000 55-year-old patients with ht 
(systolic and diastolic blood pressure ≥140 and 90 mmHg, 
respectively), without cVD complications (angina pectoris 
(AP), acute myocardial infarction (AMi), heart failure (hF) 
and/or stroke) or left ventricular hypertrophy, with a cholesterol 
level of less than 200 mg/dl and a hDl-c level above 60 mg/
dl was run through the model from the starting point. 
comparator strategies were antihypertensive therapies 
used in the clinical practice in Serbia (diuretics, beta blockers, 
ca channel antagonists and Ace inhibitors), as either mono- 
or combination therapy. combination therapy (di- and tri-
therapy) was modeled according to the clinical practice. For 
example, monotherapy with an Ace inhibitor meant inclusion 
of a diuretic (di-therapy) and a beta blocker as tri-therapy (1, 
27, 34). All therapeutic strategies were compared with the “no 
intervention” strategy, in other words patients not receiving 
any therapy. 
A Markov model was created which took into account 
the previously published analyses of the prescribing practice 
and cost of ht in Serbia (1, 27) as well as analyses of clinical 
trials of different pharmacotherapies. Previously published 
pharmacoeconomic studies (41, 52) were adapted in a way 
to reflect the current clinical practice in Serbia (di-therapy 
and tri-therapy). A Markov model was constructed using 
treeAge healthcare module version 1.5.2 (treeAge Software 
INC., Williamstown, USA). The model consists of 9 defined 
health states (Fig. 1) identical to all strategies except for “no 
intervention”. At the beginning patients were assumed not to 
have any cardiovascular comorbidity. the arrows show cohort 
movement through the model. At any point in time a patient 
can be in only one of the states. 
the cycle length that determined the stay of the cohort in 
a particular stage was defined to last 6 months. During this 
period the patient could be in only one of the defined states. 
the 6-month period was chosen under the assumption that it is 
possible to develop only one complication during that period 
and that add-in therapy takes place every six months. 
Fig. 1. Bubble diagram for health states in the Markov model. * in the case 
of “no intervention” there are no mono-, di- or tri- therapies. AMi – acute 
myocardial infarction; AP – angina pectoris; hF – heart failure.
complications of ht (AMi, AP, hF or stroke and their 
combinations) and total mortality were observed as outcomes. 
other cVD complications were not included in the model due 
to inadequate data in the literature. 
the time-horizon of the study was the lifetime of the 
patient or 100 years of age due to the assumption that 99% of 
the cohort would die at that age.
Probabilities
Patient transition through the model was defined by transition 
probabilities describing the likelihood of moving within states 
over each model cycle. All probabilities were calculated 
from large prospective studies using the formula: p = 1 – 
exp {- rt}, where p is the probability, r is the rate and t is the 
time period of interest (3, 45). the transition probability for 
cardiovascular events (AMi, AP) and mortality after AMi, AP 
for “no intervention” was calculated from the Serbian Acute 
coronary Syndrome Registry (24) depending on the age of the 
subject. Due to the unavailability of the probability data for 
hF and stroke, we assumed the same probability as for AMi. 
the probability of dying from a non-cVD event was based on 
Serbian life expectancy tables which depend on age (26). Six-
month transition probabilities for the cohort are shown in the 
Appendix (see the Supplementary Appendix available at www.
diagnosisp.com) with the corresponding references (2, 4, 8, 10, 
11, 12, 13, 19, 21, 23, 24, 26, 28, 44, 50, 51, 53). 
Patient adherence to the therapy was also included in 
the model. Meta-analysis of the effects of different blood-
pressure-lowering drugs showed a very similar discontinuation 
rate between all antihypertensive drugs. About three-quarters 
of all patients remained on their assigned treatments at the 
end of the follow-up (mean 4.9 years) (42).  the StoP-
hypertension-2 trial (20) showed that there was no difference 
in patient adherence to therapy and the non-adherence rate was 
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37.7%, 37.7%, 33.8% and 38.7% for diuretics, beta blockers, 
ca channel antagonists and Ace inhibitors, respectively, 
for a 60-month follow-up period. We calculated six-month 
probabilities using the above formula and non-adherence data 
from StoP-hypertension-2 trial. 
Costs
only direct medical costs were taken into consideration. costs 
of medicines, office visits to physicians, hospitalisations and 
surgical interventions were expressed in euros (€) using the 
2009 average exchange rate to convert the Serbian dinar to the 
€ (€1 = 94.12 RSD). All costs were taken from the Serbian 
Republic institute for health insurance (Rihi) price list and 
are summarised in Table 1. Given the current legislation, it 
was assumed that the patient had six visits to a GP and two, to 
a cardiologist per year. 
TABLE 1
costs used in the model (2009 values)
Comparator Value (€)
Diuretic (furosemide) 5.57
Beta blocker (metoprolol) 18.13
ca channel blocker (amlodipine) 19.97
Ace inhibitor (enalapril) 15.10
Statins (simvastatin) 18.78
ticlopidine 60.22
clopidogrel 79.58
Warfarin 11.32
Acenocoumarol 7.05
hospital day (intensive cardiovascular surgery) 56.03
hospital day (general cardiovascular surgery) 20.88
Rehabilition stroke – 1 day 12.22
Rehabilition acute myocardial infraction/angina 
pectoris – 1 day 11.16
Visit to general practitioner (every 2 months) 4.90
Visit to cardiologist (once in 6 months) 1.99
Acute miocardial infarction event 3204.23
Angina pectoris event 3196.18
heart failure event 3575.49
Stroke event 2346.41
two or more complications 6160.16
For base case analysis the medicine’s cost was for the most 
commonly used medicine from the given therapeutic class in a 
defined daily dose (for example, enalapril 20 mg daily). Drug 
utilization data were obtained from the Rihi. 
the costs of complications were calculated as the sum of 
hospitalisation cost, cost of surgical intervention [coronary 
artery bypass grafting (cABG) or percutaneous transluminal 
coronary angioplasty (PtcA)], cost of medication administered 
and costs for rehabilitation. 
the average number of hospital days spent in intensive 
care units were 7.81, 9.06, 9.00 and 10.00 for AP, AMi, hF 
and strokes, respectively (25). the rehabilitation patients spent 
on average 2, 3, 3 and 4 weeks per cycle for AP, AMi, hF and 
strokes, respectively.
the cost of an AMi event includes application of 
streptokinase (in 13% of patients), heparin (21%), lidocaine 
(15.4%), amiodarone (9.8%), dopamine (10.4%), cABG 
intervention (26%), cost of PtcA with drug-eluting stent 
implantation (74%), complete blood analysis with additional 
analysis of c-reactive protein, creatine kinase, myoglobin 
and troponin; echocardiogram, electrocardiogram, coronary 
angiography with the application of intravenous anesthetic, 
hospitalisation days (7.81) and an ergometric test one month 
after the AMi event and rehabilitation for three weeks. AP 
event costs include cost of cABG intervention (in 26% of 
patients), cost of PtcA with drug-eluting stent implantation 
(74%), complete blood analysis with additional analysis, 
the same as in the case of an AMi event, echocardiogram, 
electrocardiogram, coronary angiography with the application 
of intravenous anesthetic, hospitalisation days (9.06) and an 
ergometric test one month after the AMi event and rehabilitation 
for two weeks. the costs of hF include cost of cABG 
intervention (in 18% of patients), cost of PtcA with drug-
eluting stent implantation (49%) valve surgery (20%), cost 
of pacemaker (10%), complete blood analysis with additional 
analysis of troponin, natriuretic peptide and renal function, 
echocardiogram, electrocardiogram, chest X-ray, ergometric 
test, coronary angiography with the application of intravenous 
anesthetic, 10 hospitalisation days and rehabilitation for three 
weeks. The costs of stroke include application of fibrinolytic 
recombinant tissue-type plasminogen activator within 3 hours 
of the cerebrovascular event at a dose of 0.9 mg per kg of body 
weight, the use of antipyretics, anxiolytics, anticonvulsants 
and antibiotics (to prevent urinary infections), neurological 
examination, brain ct, magnetic resonance imaging of the 
head, anticoagulant therapy (heparin and its derivatives in the 
stationary settings), measurement of pro-thrombin time after the 
introduction of thrombolytic therapy, electroencephalography, 
transcranial doppler, 10 hospitalisation days and rehabilitation 
for four weeks. 
Utilities
the utility measurement included in the analysis was quality-
adjusted life years (qAlY). qAlY can have a value between 
0 and 1, where 0 represents death and 1 represents a health 
state equal to perfect health. Due to the unavailability of utility 
values in Serbia, we obtained utility data from the harvard 
cost-effectiveness analysis registry database (7). the same 
database and adequately extracted data from the database have 
been used by previous cost-effectiveness studies conducted 
in canada (52) and the UK (41). During analysis utility loss 
from the adverse effects of treatment was not taken into 
account, because most of the published cost-effectivenesss 
studies assumed minimal loss (0.01 or less) (7, 41). in cases 
of combined therapy utility was obtained by multiplying 
monotherapy utilities, for example di-therapy on a diuretic and 
a beta blocker resulted in a utility value of 0.9492, obtained 
as the product of the utility value associated with the diuretic 
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(0.9494) and the utility value associated with the beta blocker 
(0.9998). the same applies to two or more complications. 
Utility values used in the model are summarised in Table 2. 
Cost-effectiveness analysis
Analyses were performed from a third-party payer perspective. 
the Rihi is the leading health care payer responsible for the 
health care of almost all the Serbian population (7.5 million 
inhabitants). An annual discount rate of 5% was applied to all 
future costs and effects (47).
the results of the analysis are presented as incremental 
cost-effectiveness ratio (iceR) which represents additional 
costs per additional effectiveness of each alternative strategy 
compared to “no intervention” or another strategy. Due to the 
fact that Serbia does not have an established iceR threshold for 
acceptance, we used Who-choice (choosing interventions 
that are cost-effective) methodology. Strategies that have cost 
effectiveness ratios below three times the GDP per capita are 
cost-effective, while strategies that have ratios below GDP 
per capita are highly cost-effective (40). in 2008 the GDP per 
capita was €4546.5, or US$6647.
the uncertainty of the model was tested through 
probabilistic sensitivity analysis using Monte-carlo simulation. 
ten thousand simulations were performed. in every simulation, 
each input parameter (probability, cost and utility) was 
sampled from the defined distribution of that parameter. The 
distributions were chosen based on the previously published 
work by Briggs et al. (3). Due to the fact that the costs are 
constrained to be positive, we used gamma distribution to 
represent uncertainty associated with this parameter. For 
utilities we chose a uniform distribution between the given 
ranges (Table 2). Since probabilities are bounded by 0 and 1 
we used Dirichlet distribution to describe probabilities for the 
given events. Results from the probabilistic sensitivity analysis 
are reported as cost-effectiveness acceptability curves (33).
TABLE 2
Utility used in the Markov model
Utility for the given state
Value 
(QALY)
Range (QALY)
no intervention 0.8580 0.7440 – 1.0000
Monotherapy with diuretic 0.9494 0.8484 – 1.0000
Monotherapy with beta blocker 0.9998 0.9998 – 1.0000
Monotherapy with ca channel 
blocker 0.8517 0.7385 – 0.9927
Monotherapy with Ace inhibitor 0.9234 0.8480 – 0.9988
Acute myocardial infarction 0.7571 0.6900 – 0.9700
Angina pectoris 0.8567 0.6900  - 0.9700
heart failure 0.6800 0.3000 – 0.9700
Stroke 0.6070 0.3500 – 0.8550
two or more complications 0.4750 0.3646 – 0.5609
Death 0
Results and Discussion
Table 3 shows the lifelong predictions of costs, qAlYs and 
cost-effectiveness. there were small differences in qAlYs 
between Ace inhibitor, beta blocker and diuretic strategies. 
the marginal effectiveness for the diuretic strategy compared 
with “no intervention” was 5.10 qAlY and that of the beta 
blocker strategy compared with the diuretic strategy was 0.73 
qAlY. the iceR for the diuretic strategy compared to “no 
intervention” was just €74.27/qAlY. the iceR for the beta 
blocker strategy compared to the diuretic strategy was €75.58/
qAlY. the ca channel blocker was dominated, meaning that 
the strategy had higher costs and less effectiveness compared 
to the other strategies.
Ace inhibitors were excluded from the analysis due to 
extended (or weak) dominance, meaning that Ace inhibitors 
were dominated by a linear combination of diuretics and beta 
blockers.
 TABLE 3
Results for base-case analysis (cost and effectiveness are discounted at 5% per year)
Comparator Cost (€) ∆ Cost (€)
Effectiveness 
(QALY)
∆ Effectiveness 
(QALY)
C/E  (€/QALY) ICER (€/QALY)
no intervention 699.0 8.67 80.64
Diuretic 1078.0 379.0 13.77 5.10 78.28 74.27
Ace inhibitor 1112.6 34.6 13.82 0.05 80.49 679.96
Beta blocker 1136.7 24.1 14.55 0.73 78.13 33.20
ca channel blocker 1142.9 6.2 12.25 - 2.29 93.26 dominated
Results after the exclusion of dominated options (simple or extended)
no intervention 699.0 8.67 80.64
Diuretic 1078.0 379.0 13.77 5.10 78.28 74.27
Beta blocker 1136.7 58.7 14.55 0.78 78.13 75.58
∆ = difference in; qAlY= quality adjusted life years; iceR = incremental cost-effectiveness ratio
3070 Biotechnol. & Biotechnol. eq. 26/2012/3
Strategies that had the best cost effectiveness ratio 
formed an efficiency frontier. These were “no intervention”, 
diuretics and beta blockers. Dominated strategies (simple or 
extended) lay on the left of the efficiency frontier. Graphical 
representation of the efficiency frontier is given in Fig. 2.
Fig. 2. Efficiency frontier for comparator strategies for treatment of patients 
with arterial hypertension. 
As the Monte carlo simulation was used, probabilistic 
sensitivity analysis was performed. Application of 
antihypertensive therapy was cost-effective even at minimal 
willingness to pay (less than €200/qAlY). cost-effectiveness 
acceptability curves in Fig. 3 show the probability that the 
antihypertensive strategies were cost effective for different 
wilingness to pay thresholds for a qAlY. the y-axis curve 
intercepts were above zero, indicating that in a small percentage 
of cases antihypertensive strategies could even be cost saving 
(for diuretics, beta blockers, calcium ion channel blockers and 
Ace inhibitors in 11.34%, 13.33%, 17.93% and 7.23% of the 
cases, respectively). three cost-effectiveness acceptability 
curves (diuretics, beta blockers and Ace inhibitors) had very 
similar probabilties of being cost-effective.
Fig. 3. cost-effectiveness acceptability curve indicating the probability that 
the antihypertensive therapy is cost effective compared to “no treatment” at 
different willingness to pay.
the results of the cost-effectiveness evaluation suggest 
that antihypertensive treatment has gain in qAlY compared 
to “no intervention”. the differences between treatments are 
small, except in the case of ca channel blockers, compared 
to other antihypertensive therapies. the results of our study 
are in agreement with results from the pharmacoeconomic 
study conducted in Germany (16) and Spain (35). From 
the perspective of the national health insurance funds, 
antihypertensive treatment prolongs patients’ life and affects 
patients’ quality of life with relatively modest increase in the 
health care expenditure compared to “no intervention”.
in our study, antihypertensive treatment (regardless of the 
anatomical therapeutic chemical (Atc) group of medicines) 
was a highly cost-effective intervention, with the cost-
effectivness ratio falling far below the chosen threshold (40). 
Similar results were demonstrated by Montgomery et al. 
(39) where the antihypertensive treatment for low-risk men 
and women aged 50-59 were £1010 and £1917 per qAlY, 
compared to untreated individuals.
We show that the use of diuretics is the most cost-effective 
strategy to start hypertensive therapy. Pharmacoeconomic 
evaluations in the UK (41), canada (52), Spain (35) and 
Greece (49) showed that the most cost-effective strategy as 
first-line therapy was thiazide diuretics. In all of the countries 
diuretics were the least costly strategy; in some cases the cost 
of diuretics was lower than the “no intervention” strategy 
(US$ 3163 for diuretic vs. US$ 4189 for “no intervention” 
for males aged 55 having a 150 mmhg systolic blood 
pressure) (52). the difference between our study and the 
abovementioned studies is that we included the sulfonamide 
diuretic furosemide in our analysis based on the prescribing 
practice in Serbia (1, 27), while other studies focused on 
thiazide diuretics. We assumed the same efficacy for all 
drugs in a given drug class. if the cost of thiazide diuretic 
was included in the pharmacoeconomic evaluation instead 
of sulfonamide diuretics, the iceR for diuretics would have 
been even smaller, as the cost of hidrochlortiazide therapy is 
lower than that of furosemide therapySerbian recomendations 
(38) are consistent with those of the european Society of 
hypertension and the european Society of cardiology (34) 
and recommend usage of all major classes of antihypertensive 
agents for the initiation and maintenance of antihypertensive 
treatment either as monotherapy or in combination. on the 
other hand, Jnc-7 guidelines (9) and British hypertension 
Society guidelines (54) recommend thiazide-type diuretics 
as the preferred initial agent. Diuretics are used sparsely in 
Serbia; in 2009 only 10% of all antihypertensive medications 
prescribed were diuretics, of which 70% where loop diuretics 
(1, 27). in Serbia and some neighbouring countries Ace 
inhibitors are frequently prescribed (1, 27, 36). the results of 
this cost-effectiveness study suggest that Ace inhibitors are 
not a cost-effective strategy. they are a less effective and more 
costly option compared to diuretics. the cost-effectiveness of 
ACE inhibitors as first-line antihypertensive therapy has been 
estimated using a Markov model in a canadian population 
(43). the results of this study showed that the qAlY gain 
in patients on Ace inhibitors was very small and that Ace 
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inhibitors had an unfavorable iceR (almost 1 million US$ 
per qAlY) when compared with conventional therapy, beta 
blockers or diuretics. 
According to the Serbian guidelines for arterial hypertension, 
the Framingham risk score (FRS) and Systematic coronary 
Risk evaluation (ScoRe) can both be used to determine 
absolute cVD risk. the guidelines postulated that the ScoRe 
system was the perfered one. however, in our previous work 
(30) we examined the accuracy and applicability of the FRS to 
the Serbian population. the accuracy of FRS in a study of 385 
participants was 85.4%. After internal validation of the results 
in which the jack-knife method was used, the jack-knifed 
coefficients implied that there was little over-expresion in the 
estimated predictive accuracy of the FRS model. 
All analysed antihypertensive medications are on the 
Rihi reimbursement list. For the majority of medications the 
patients only have to pay € 0.53 per prescription. there are 
only a few drugs that cost more. one is carvedilol (€ 1.60 per 
dispensed drug).
the cost-effectiveness ratio obtained in our study had a 
lower value than that found in studies conducted in the more 
economically developed european countries. this can be 
explained by the lower costs of antihypertensive medication, 
labour costs, hospital days and surgical intervention in Serbia 
than in developed european countries.
considering the incidence of hypertension in a 55- to 
64-year-old patient cohort and the percentage of patients 
adherent to their therapy (37), it can be expected that there 
would be 114,000 new hypertensive patients in 2011. if the 
current trend in antihypertensive drug utilisation is maintained, 
an increase in Rihi expenditures of about 5% (€ 5.6 milion) in 
2011 could be expected.
To our knowledge this is the first Markov model focusing 
on all available therapeutic approaches for hypertension 
pharmacotherapy in Serbia. Accordingly it has several 
limitations.
in the literature there is a lack of studies that directly 
(head-to-head) compare the effects of antihypertensive 
therapy. We found a few meta-analyses that examined the 
health outcomes associated with various antihypertensive 
treatments (46, 48, 55). however, inadequate data for the 
numerous probabilities were used in the models. therefore, 
the effectiveness of the antihypertensive therapies used in the 
models is based on indirect comparisons which can cause an 
error in the assessment of results of antihypertensive drugs. 
the same method was used in other pharmacoeconomic 
studies conducted in the UK and canada (41, 52). Due to the 
lack of adequate studies, we conducted a sensitivity analysis. 
it was performed on a cohort of patients aged 55. the obtained 
results should not be extrapolated to younger or to older 
patients, since several pharmacoeconomic studies have shown 
that ICER values (regardless of strategy) are significantly 
higher in younger patients, and significantly lower in older 
patients when compared with the patients chosen as subjects in 
the analyzed cohort (16, 35, 39, 41). 
the Markov model in our study included only major ht 
cVD complications including AMi, AP, hF and stroke. it 
did not include other ht complications such as diabetes or 
renal failure. on the basis of these differences the model can 
be explained by differences in the results of the analysis in 
relation to nice’s (national institute of clinical excellence) 
model (41).
Conclusions
Based on the results of cost-effectiveness we concluded that 
all types of antihypertensive medicines increased the life 
expectancy of patients with ht. the highest gain was seen in 
patients receiving diuretics. For individuals aged 55 diuretics 
are the most cost-effective strategy to start hypertensive 
monotherapy in Serbia, which is in accordance with the 
available medicines and their market prices. Despite local 
guidelines recommending all antihypertensive agents as first-
line therapy, prescribing solely diuretics would be more cost-
effective.
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